ASCO 2026 Highlights: New Advances in Prostate Cancer Care Improve Outcomes and Quality of Life

The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting brought some very encouraging news for the prostate cancer community. Black men have the highest risk of prostate cancer worldwide. They are about 70 percent more likely to be diagnosed and more than twice as likely to die from the disease compared to white men. Now, experts are seeing a clear shift toward treatments that are more powerful, more precise, and, most importantly, more focused on a patient’s overall quality of life.

BlackDoctor spoke with Dr. Tanya Dorff, a medical oncologist and leader of the genitourinary cancer program at City of Hope, to explain what these advancements mean for you and your loved ones.

A New Hope: The ABBV-969 Study

One of the most exciting findings this year is a new dual-targeted drug called ABBV-969.

What Is It?

It’s an antibody-drug conjugate. You can think of it like a smart missile. It finds prostate cancer cells by targeting two specific proteins (STEAP1 and PSMA), then delivers a potent, cell-killing treatment directly to them.

In a group of 49 patients who had already tried several other treatments, such as hormone therapy and chemotherapy, the results were impressive:

• Strong response: Nearly seven out of 10 patients experienced a significant drop in their PSA levels, and these benefits lasted an average of 11 months.
• Tumor shrinkage: About 45 percent of patients saw their tumors get smaller, and some even had a complete response, which means no signs of cancer were found on scans.
• Staying power: On average, it took 15.3 months before the cancer started to grow again.

What This Means for Patients and Providers

This drug gives new hope to people who have already tried standard treatments. While there are side effects, doctors can manage them by changing the dose. Even in advanced stages, experts are finding better ways to fight back.

What’s Next?

Besides new drugs, the discussion at ASCO is changing in two important ways:

• Hitting harder, earlier: Doctors are finding that the harder you hit prostate cancer from the get-go, the longer the period of remission and the better the quality of life. More powerful treatments, such as PARP inhibitors, are now being used earlier in the treatment process.
• The next generation of radiopharmaceuticals: Lutetium-177, a common radioactive treatment, is already a standard. Now, researchers are testing Actinium-based therapies, which could offer even better results for patients.

A Note on Quality of Life

It’s not just about living longer; it’s also about living better. Dr. Dorff pointed out that the medical community is now focusing more on the whole patient experience.

Researchers are beginning to study:

• Treatment holidays: Studies like A-DREAM are looking at whether men can safely take breaks from ongoing hormone therapy.
• Cognitive health: Studies like ARACOG are examining how different treatments affect brain function and memory. This helps doctors choose options that better protect patients’ daily quality of life.

Clinical Implications for Providers

Emerging targeted therapies, earlier treatment intensification strategies, and increased attention to survivorship outcomes may help clinicians optimize care for patients with advanced prostate cancer, while reinforcing the importance of clinical trial participation and quality-of-life assessments throughout the treatment journey.

Dr. Dorff’s insights remind us that with each conference, the path forward gets a little brighter, bringing more options to help patients live longer and better.

Are you a healthcare professional? Register with us today!